SEC Form 4 · accession 0001698262-26-000005
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William E. Rote
Officer — Chief Research Officer
Period of report
Sep 15, 2026
Accepted (ET)
Sep 17, 2026 · 9:35 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 15, 2026 | M | 39,000 | $25.25 | A | 154,745 | D | |
| Common Stock | Sep 15, 2026 | M | 39,650 | $17.96 | A | 194,395 | D | |
| Common StockF3 | Sep 15, 2026 | S | 63,907 | $61.994 | D | 130,488 | D | |
| Common StockF4 | Sep 15, 2026 | S | 29,021 | $62.6552 | D | 101,467 | D | |
| Common StockF5 | Sep 15, 2026 | S | 3,000 | $63.6508 | D | 98,467 | D | |
| Common Stock | Sep 15, 2026 | S | 270 | $65.31 | D | 98,197 | D | |
| Common Stock | Sep 16, 2026 | M | 350 | $17.96 | A | 98,547 | D | |
| Common Stock | Sep 16, 2026 | M | 55,000 | $15.46 | A | 153,547 | D | |
| Common Stock | Sep 16, 2026 | M | 57,500 | $26.88 | A | 211,047 | D | |
| Common StockF6 | Sep 16, 2026 | S | 65,104 | $63.1205 | D | 145,943 | D | |
| Common StockF7 | Sep 16, 2026 | S | 47,746 | $63.6126 | D | 98,197 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee stock option (right to buy)F8 | $25.25 | Sep 15, 2026 | M | 39,000 | D | — | May 10, 2028 | Common Stock | 39,000 | 0 | D |
| Employee stock option (right to buy)F8 | $17.96 | Sep 15, 2026 | M | 39,650 | D | — | May 9, 2029 | Common Stock | 39,650 | 350 | D |
| Employee stock option (right to buy)F8 | $17.96 | Sep 16, 2026 | M | 350 | D | — | May 9, 2029 | Common Stock | 350 | 0 | D |
| Employee stock option (right to buy)F8 | $15.46 | Sep 16, 2026 | M | 55,000 | D | — | Jan 31, 2030 | Common Stock | 55,000 | 0 | D |
| Employee stock option (right to buy)F8 | $26.88 | Sep 16, 2026 | M | 57,500 | D | — | Jan 21, 2031 | Common Stock | 57,500 | 0 | D |
Explanation of responses
- F1Includes 271 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026.
- F2This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- F3The weighted average sale price for the transaction reported was $61.994, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F4The weighted average sale price for the transaction reported was $62.6552 and the range of prices were between $62.41 and $63.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F5The weighted average sale price for the transaction reported was $63.6508, and the range of prices were between $63.49 and $63.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided
- F6The weighted average sale price for the transaction reported was $63.1205, and the range of prices were between $62.47 and $63.4650. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F7The weighted average sale price for the transaction reported was $63.6126, and the range of prices were between $63.47 and $63.96. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F8The stock option is fully vested and exercisable.